Trial Outcomes & Findings for Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People (NCT NCT00919724)

NCT ID: NCT00919724

Last Updated: 2014-07-15

Results Overview

The maximum change in brachial artery diameter after induction of reactive hyperemia post-release of vascular occlusion. This is a measure of the ability of the endothelium to respond appropriately to lack of tissue oxygenation distal to the point of brachial artery compression.

Recruitment status

COMPLETED

Target enrollment

89 participants

Primary outcome timeframe

Single measurement

Results posted on

2014-07-15

Participant Flow

Participant milestones

Participant milestones
Measure
HIV-Infected
HIV-infected participants who are not currently receiving antiretroviral medications
HIV-Uninfected
HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
Overall Study
STARTED
45
44
Overall Study
COMPLETED
45
44
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
HIV-Infected
n=45 Participants
HIV-infected participants who are not currently receiving antiretroviral medications
HIV-Uninfected
n=44 Participants
HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
Total
n=89 Participants
Total of all reporting groups
Age, Continuous
35 years
n=5 Participants
35 years
n=7 Participants
35 years
n=5 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
11 Participants
n=7 Participants
21 Participants
n=5 Participants
Sex: Female, Male
Male
35 Participants
n=5 Participants
33 Participants
n=7 Participants
68 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
28 Participants
n=5 Participants
14 Participants
n=7 Participants
42 Participants
n=5 Participants
Race (NIH/OMB)
White
17 Participants
n=5 Participants
30 Participants
n=7 Participants
47 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Single measurement

The maximum change in brachial artery diameter after induction of reactive hyperemia post-release of vascular occlusion. This is a measure of the ability of the endothelium to respond appropriately to lack of tissue oxygenation distal to the point of brachial artery compression.

Outcome measures

Outcome measures
Measure
HIV-Infected
n=45 Participants
HIV-infected participants who are not currently receiving antiretroviral medications
HIV-Uninfected
n=44 Participants
HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
Endothelial Function (Brachial Artery Reactivity)
3.98 percent dilation
Standard Deviation 2.95 • Interval 1.91 to 4.99
3.37 percent dilation
Standard Deviation 2.74 • Interval 1.2 to 4.59

Adverse Events

HIV-Infected

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

HIV-Uninfected

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Samir K. Gupta, MD, MS

Indiana University School of Medicine

Phone: 317-274-7926

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place